ea0056gp205 | Pituitary Clinical | ECE2018
Witek Przemyslaw
, Biller Beverly M K
, Lacroix Andre
, Feelders Richard
, Li Yiming
, Geer Eliza B
, Brue Thierry
, Ravichandran Shoba
, Tauchmanova Libuse
, Roughton Michael
, Petersenn Stephan
Introduction: Long-acting pasireotide reduced urinary free cortisol (UFC) in most patients with Cushings disease (CD) during a large Phase III study (Lacroix et al. Lancet Diabetes Endocrinol 2018). The analyses presented here explored the impact of baseline characteristics on response to long-acting pasireotide.Methods: 150 patients with persistent, recurrent or de novo CD and mean UFC (mUFC; from three 24-hour samples collected ...